European Vaccine Initiative (EVI)

#PrIMAVeRa_AMR partners got together to advance AMR modelling in a workshop hosted by UMC Utrecht. 🎯 The focus? Refining and expanding #MathematicalModels to better evaluate the cost-effectiveness of vaccination and monoclonal antibody strategies in the fight against antimicrobial resistance (#AMR). Discussions covered pathogen-specific modelling, antibiotic consumption trends, and data stratification—key to improving model accuracy. The meeting wrapped up with clear next steps, reinforcing our commitment to tackling this urgent public health challenge. 🦠💊🔬 Read more ➡ https://lnkd.in/g3vDbQbF  --- #Eufunded #StopSuperbugs Innovative Health Initiative (IHI)

📢 Today is #WorldTBDay! 🦠🚨 #Tuberculosis remains one of the deadliest infectious diseases, claiming 1.25 million lives in 2023 alone. With strong commitment, increased investment, and global collaboration, we can develop life-saving #vaccines and innovative solutions to defeat TB. Organisations like TuBerculosis Vaccine Initiative (TBVI) and European Vaccine Initiative (EVI) are leading the charge by accelerating vaccine research, AI-based technologies for diagnostics and policies for antimicrobial resistance (#AMR) and strengthening partnerships worldwide. 🌍🔬 Join us in raising awareness and advocating for action! Together, we can make TB history. Read more about TBVI and EVI’s work: https://lnkd.in/dijrbFuX #EndTB #YesWeCanEndTB #Antimicrobialresistance #StopSuperbugs

🔬 In February 2025, #PrIMAVeRa_AMR joined fellow AMR Accelerator projects in Basel for insightful discussions on advancing antimicrobial resistance (#AMR) research. Irina Meln, PhD presented PrIMAVeRa’s latest progress alongside updates from COMBINE, UNITE4TB, RespiriTB/RespiriNTM, GNA NOW and ERA4TB. A key highlight was a workshop on project sustainability, sparking crucial conversations on ensuring long-term impact in AMR innovation.  ▶️ https://lnkd.in/dQbUQpNi PrIMAVeRa is proud to collaborate with leading experts in the fight against AMR—together, we’re driving real solutions! 💊🌍  --- #Eufunded #StopSuperbugs - Innovative Health Initiative (IHI)

  This week, we had the pleasure of welcoming the Kintampo Health Research Centre (KHRC) team to European Vaccine Initiative (EVI) in Heidelberg, Germany - a visit that reaffirms a strong and productive collaboration dating back to 2011. Our partnership began with the eICT project, funded by EDCTP, on "Evaluating the impact of malaria clinical trials on the delivery of health care,  particularly for women and children, in sub-Saharan Africa"; and has since flourished, driving impactful research and innovation in infectious disease control. Over the years, we have continued to work together towards advancing vaccine development and global health solutions, demonstrating the power of long-term collaboration.   Thank you to Kwaku Poku Asante, Thomas Gyan, Abdul Karimu Alhassan, Martin Dzimabi for the fruitful discussions and insights into strengthening partnerships. We look forward to many more years of impactful work together! 🤝

The #PrIMAVeRa_AMR consortium celebrates the acceptance of its newly produced video 📽️ to be presented at #ESCMIDGlobal Event 2025 in Vienna! This video gives an accessible introduction to the project’s goals and methods, and includes interviews with key partners including: -       Dr. Irina Meln, PhD, Project Coordinator, of the European Vaccine Initiative (EVI) Vaccine Initiative -       Dr. Marc Bonten, Scientific Lead, of the UMC Utrecht -       Dr. Venanzio Vella, EFPIA - European Federation of Pharmaceutical Industries and Associations Lead, of GSK Vaccines 📝Read more, and view the video here: https://lnkd.in/dn5DJaGb By lowering the occurrence of infectious diseases, reducing the reliance on #antibiotics, and limiting the development of #AMR within communities, #vaccines can serve as a crucial tool in combating and managing AMR, and ultimately #savelives. --- #Eufunded #StopSuperbugs #StopSuperbugs Innovative Health Initiative (IHI), AMR Accelerator  ESCMID - European Society of Clinical Microbiology and Infectious Diseases

Welcome Dr Zakariah Buwah at the European Vaccine Initiative (EVI) through the WHO-TDR Clinical Research Leadership Programme! Dr. Buwah brings valuable experience in clinical trials and #vaccine research, having worked on #malaria, COVID-19, Lassa fever, and sickle cell treatments. As a WANETAM-trained clinical trialist sponsored by EDCTP, he has also contributed to yellow fever vaccine research at MRC Gambia. He holds a Master’s in Public Health from the University of Ghana, Legon. Dr Buwah is eager to expand his expertise in clinical trial design, vaccine development, and #projectmanagement. Join us to welcome Dr Zakariah Buwah to the EVI team! —- https://lnkd.in/eXHd5kd9

We are happy to welcome our new research fellow, Dr Samiratu Yakubu! With 7 years in #clinicaltrials regulation and GCP, she brings expertise in #vaccine development and regulatory oversight. Dr. Yakubo is affiliated with the Food and Drug Authority, Ghana, and holds a master’s in clinical Drug Development from University College London. At European Vaccine Initiative (EVI) she aims to strengthen her knowledge in multi-national vaccine development, regulatory submissions, and stakeholder coordination to support vaccine trials in Ghana. Join us to welcome Dr Samiratu Yakubo to the EVI team. — https://lnkd.in/dKd4AEfR

🌍 We’re thrilled to share that the CAPTIVATE Annual Meeting successfully took place on 20-21 February 2025! CAPTIVATE partners and SEAC members came together to reflect on project achievements and shape future directions. A special highlight was hearing from our distinguished keynote speakers: 🎤 Lindsey Wu (World Health Organization) 🎤 Paul Thomas (St. Jude Children's Research Hospital, US) As we move forward, we remain dedicated to developing a new multistage #malaria #vaccine, driving innovation, and strengthening global health efforts. --- PROJECT PARTNERS Leiden University Medical Center DKFZ German Cancer Research Center ImmuneWatch NEC OncoImmunity AS Quantoom Biosciences BPRC UNSW --- #CaptivateEu #MalariaVaccine #EUFunded 🔗 Read more about the project here: captivate-malaria.eu This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101081028.

Ole Olesen, European Vaccine Initiative (EVI)’s Executive Director, discussed the future funding for global health in the EU framework programme, making the case for continued European investment in the development of #vaccines for diseases of neglected populations, such as #malaria and #tuberculosis. 🦟🦠   🎯 Read the key highlights of the Science|Business session hosted by Impact Global Health and Deutsche Stiftung Weltbevoelkerung (DSW): https://lnkd.in/dnc3EX4Q

For decades, the World Health Organization has worked with countries to #EndMalaria — 45 countries and 1 territory have been successful so far! Hope towards a malaria-free world is rising with 25 of 83 endemic countries now reporting fewer than 10 cases per year. #HealthForAll